Superseded · version 1: KPV^↗

A tripeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.^↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.

What this version reported

FDA's KPV briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.^↗↗

Organizations named in cited records:

U.S. Food and Drug Administration^↗↗

Sources for this version

1
FDA briefing document for KPV ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
2
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026